2011, nr. 3 - Academia de Ştiinţe a Moldovei

272ACI (European Academy of Allergology and ClinicalImmunology) şi ARIA (Allergic Rhinitis and its Impacton Asthma) 2008 referitor la eficacitatea clinicăîn tratamentul RA.Buletinul AŞMBibliografie selectivă1. Anatomical Therapeutic Chemical (ATC) classifi -cation index with Defi ned Daily Doses (DDD’s). WHO collaboratingCentre for Drug Statistics Methodology, Oslo,Norway. January, 2004.2. Bachert C. Decongestant effi cacy of Laevocetirizinein patients with seasonal allergic rhinitis. In: Allergy,2001, 56 (suppl. 65), p. 14-30.3. Desager J.P., Horsmans Y. Pharmacokineticpharmacodynamicrelationships of H1-antihistamines. In:Clin. Pharmacokinet, 1995, 28, p. 419-432.4. Du Buske L.M. Clinical compasion of histamineH1-receptor antagonist drugs. In: J. Allergy Clin. Immunol.,1996, 98(6 Pt 3), p. S30 7-318.5. Finn A.F. Jr., Kaplan A.P., Fretwell R., Qu R., LongJ. A double-blind, placebo-controlled trial of fexofenadineHCl in the treatment of chronic idiopathic urticaria. In: J.Allergy Clin., Immunol., 1999, 104(5), p. 1071-1078.6. Horak F., Stubner U., Zieglmayer R. et al. Onsetand duration of action of desloratadine. XIX Congress ofEurop. Academy of Allergology and Clinical Immunology,Lisbon, 2000.7. Marone G. Milestones in the biology and pharmacologyof H1-receptor antagonists. In: Allergy, 1997,52(34 Suppl), p. 7-13.8. Nelson H., Reynolds R., Mason J. FexofenadineHCl is safe and effective for treatment of chronic idiopathicurticaria. In: Ann. Allergy Asthma Immunol., 2000,84(5), p. 517-522.9. Noman P., Dimmann A., Laevocetirizin: a preclinicaland clinical overview. In: Drugs Today, 201, 37(4),p. 215-227.10. Ormerod A.D. Urticaria: recognition, causes andtreatment. In: Drugs, 1994, 48, p. 717-730.11. Ring J., Hein R., Gauger A. Desloratadine in thetreatment of chronic idiopathic urticaria. In: Allergy, 2001,56 (suppl. 65), p. 28-32.12. Simons F.E., Murray H.E., Simons K.J. Quantitationof H1-receptor anatagonists in skin and serum. In: J.Allergy Clin. Immunol., 1995, 95, p. 759-764.13. Simons F.E., Simons K.J. Clinical pharacology ofnew histamine H1-receptor antagonists. In: Clin. Pharmacokinet,1999, 36(5), p. 329-352.RezumatA fost studiat efectul preparatului xyzal în calitate deterapie de bază în rinita alergică. Administrarea preparatuluixyzal a demonstrat o activitate antihistaminică calitativă,eficacitate clinică înaltă, ce asigură controlul asuprasimptomelor inflamaţiei alergice, comparativ cu alte antihistaminice,aceste proprietăţi fiind determinate de particularităţilesale farmacologice.SummaryThere have been studied the efficacy of Xyzal drugas basic treatment in allergic rhinitis. Administration ofXyzal demonstrated antihistaminic qualitative activity,good clinical efficiency which assured the control ofallergic inflammation symptoms, compared with otherantihistamines, being determined by its pharmacologicparticularities.РезюмеБыли изучены эффективность, актуальность и безопасностьприменения нового антигистаминного препарата3-го поколения xyzal в лечении аллергическихринитов по сравнению с препаратами предыдущих 1-йи 2-й поколений.